References
Adalja, A., M. Watson, E. Toner, A. Cicero, and T. Inglesby. 2018. The characteristics of pandemic pathogens. Baltimore, MD: Johns Hopkins University.
Adeyi, O. O., E. Baris, O. B. Jonas, A. Irwin, F. C. J. Berthe, F. G. Le Gall, P. V. Marquez, I. A. Nikolic, C. A. Plante, M. Schneidman, D. E. Shriber, and A. Thiebaud. 2017. Drug-resistant infections: A threat to our economic future. Washington, DC: World Bank.
Ahammad, Z. S., T. R. Sreekrishnan, C. L. Hands, C. W. Knapp, and D. W. Graham. 2014. Increased waterborne blaNDM-1 resistance gene abundances associated with seasonal human pilgrimages to the upper Ganges River. Environmental Science & Technology 48:3014–3020.
Ahmed, S. A., E. Bariş, D. S. Go, H. Lofgren, I. Osorio-Rodarte, and K. Thierfelder. 2017. Assessing the global economic and poverty effects of antimicrobial resistance. Washington, DC: World Bank.
Ajao, A., S. V. Nystrom, L. M. Koonin, A. Patel, D. R. Howell, P. Baccam, T. Lant, E. Malatino, M. Chamberlin, and M. I. Meltzer. 2015. Assessing the capacity of the U.S. health care system to use additional mechanical ventilators during a large-scale public health emergency. Disaster Medicine and Public Health Preparedness 9:634–641.
AMR Industry Alliance. 2018. Tracking progress to address AMR. Geneva: Switzerland: AMR Industry Alliance.
Baird, S. J., R. S. Garfein, C. T. McIntosh, and B. Ozier. 2012. Effect of a cash transfer pro-gramme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: A cluster randomised trial. The Lancet 379(9823):1320–1329.
Bali, S., K. A. Stewart, and M. A. Pate. 2016. Long shadow of fear in an epidemic: Fearonomic effects of Ebola on the private sector in Nigeria. BMJ Global Health 1:e000111.
Barrett, S. 2013. Economic considerations for the eradication endgame. Philosophical Transactions of the Royal Society B Biological Sciences 368(1623). London: The Royal Society Publishing.
Beardmore, R. E., R. Peña-Miller, F. Gori, and J. Iredell. 2017. Antibiotic cycling and antibiotic mixing: Which one best mitigates antibiotic resistance? Molecular Biology and Evolution 3(4):802–817.
Berry, K., T. Allen, R. D. Horan, J. F. Shogren, D. Finnoff, and P. Daszak. 2018. The economic case for a pandemic fund. EcoHealth 15(2):244–258.
Braden, C. R., S. F. Dowell, D. B. Jernigan, and J. M. Hughes. 2013. Progress in global surveillance and response capacity 10 years after severe acute respiratory syndrome. Emerging Infectious Disease 19(6):864–869.
Burns, A., D. v. d. Mensbrugghe, and H. Timmer. 2006. Evaluating the economic consequences of avian influenza. Washington, DC: World Bank.
CDC (U.S. Centers for Disease Control and Prevention). 2016a. Cost of the Ebola epidemic. https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/cost-of-ebola.html (accessed August 23, 2018).
CDC. 2016b. Smallpox. https://www.cdc.gov/smallpox/clinicians/clinical-disease.html (accessed August 23, 2018).
CDC. 2018. One Health. https://www.cdc.gov/onehealth/index.html (accessed August 23, 2018).
CGDEV (Center for Global Development). 2007. Case 1: Eradicating smallpox. Washington, DC: Center for Global Development.
Choi, B. C. K., and A. W. P. Pak. 2003. A simple approximate mathematical model to predict the number of severe acute respiratory syndrome cases and deaths. Journal of Epidemiology and Community Health 57(10):831.
Cochi, S. 2017. Pivoting from polio eradication to measles and rubella elimination: A transition that makes sense both for children and immunization program improvement. The Pan African Medical Journal 27(Suppl 3):10.
Copeland, D. L., R. Basurto-Davila, W. Chung, A. Kurian, D. B. Fishbein, P. Szymanowski, J. Zipprich, H. Lipman, M. S. Cetron, M. I. Meltzer, and F. Averhoff. 2013. Effectiveness of a school district closure for pandemic influenza A (H1N1) on acute respiratory illnesses in the community: A natural experiment. Clinical Infectious Diseases 56:509–516.
Dawood, F. S., A. D. Iuliano, C. Reed, M. I. Meltzer, D. K. Shay, P.-Y. Cheng, D. Bandaranayake, R. F. Breiman, W. A. Brooks, P. Buchy, D. R. Feikin, K. B. Fowler, A. Gordon, N. T. Hien, P. Horby, Q. S. Huang, M. A. Katz, A. Krishnan, R. Lal, J. M. Montgomery, K. Mølbak, R. Pebody, A. M. Presanis, H. Razuri, A. Steens, Y. O. Tinoco, J. Wallinga, H. Yu, S. Vong, J. Bresee, and M.-A. Widdowson. 2012. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study. Lancet Infectious Diseases 12:687–695.
DFID (U.K. Department for International Development)-Wellcome Trust. 2018. DFID-Wellcome joint initiative on epidemic preparedness call for proposal. London: U.K. Department for International Development-Wellcome Trust.
Dolgin, E. 2018. Bringing down the cost of cancer treatment. In Nature outlook: The future of medicine. Nature 555(Suppl):S26–S29.
Drake, T. L., Z. Chalabi, and R. Coker. 2012. Cost-effectiveness analysis of pandemic preparedness: What’s missing? Bulletin of the World Health Organization 90:940–941.
Eubank, S., H. Guclu, V. S. Anil Kumar, M. V. Marathe, A. Srinivasan, Z. Toroczkai, and N. Wang. 2004. Modelling disease outbreaks in realistic urban social networks. Nature 429:180–184.
Fan, E. X. 2003. SARS: Economic impacts and implications. Manila, Philippines: Asian Development Bank.
Fan, V. Y., D. T. Jamison, and L. H. Summers. 2016. The inclusive cost of pandemic influenza risk. National Bureau of Economic Research Working Paper No. 22137. Cambridge, MA: National Bureau of Economic Research.
Fan, V. Y., D. T. Jamison, and L. H. Summers. 2018. Pandemic risk: How large are the expected losses? Bulletin of the World Health Organization 96:129–134.
Fenichel, E. P., C. Castillo-Chavez, M. G. Ceddia, G. Chowell, P. A. G. Parra, G. J. Hickling, G. Holloway, R. Horan, B. Morin, C. Perrings, M. Springborn, L. Velazquez, and C. Villalobos. 2011. Adaptive human behavior in epidemiological models. Proceedings of the National Academy of Sciences of the United States of America 108:6306–6311.
Fonkwo, P. N. 2008. Pricing infectious disease: The economic and health implications of infectious diseases. EMBO Reports 9(Suppl 1):S13–S17.
Foster, N., A. Vassall, S. Cleary, L. Cunnama, G. Churchyard, and E. Sinanovic. 2015. The economic burden of TB diagnosis and treatment in South Africa. Social Science & Medicine 130:42–50.
Fox, M. P., S. Rosen, W. B. MacLeod, M. Wasunna, M. Bii, G. Foglia, and J. L. Simon. 2004. The impact of HIV/AIDS on labour productivity in Kenya. Tropical Medicine & International Health 9:318–324.
G7 Leaders (Group of Seven Leaders). 2015. Defending liberty and improving quality of life: Leaders declaration G7 Summit, June 7–8. Elmau, Germany: European Commission.
G20 Leaders (Group of Twenty Leaders). 2017. G20 Leaders’ declaration: Shaping an interconnected world. Hamburg, Germany: European Commission.
GHRF (Global Health Risk Framework) Commission. 2016. The neglected dimension of global security: A framework to counter infectious disease crises. Washington, DC: The National Academies Press.
The Global Fund (The Global Fund to Fight AIDS, Tuberculosis and Malaria). 2018. Results report 2018. Geneva: Switzerland: The Global Fund to Fight AIDS, Tuberculosis and Malaria.
GPEI (Global Polio Eradication Initiative). 2017. Fact sheet: Vaccine derived poliovirus (VDPV). Geneva, Switzerland: World Health Organization. http://polioeradication.org/wp-content/uploads/2017/09/GPEI-cVDPV-factsheet_September-2017.pdf (accessed August 23, 2018).
Horton, S., H. Gellband, D. Jamison, C. Levin, R. Nugent, and D. Watkins. 2017. Ranking 93 health interventions for low- and middle-income countries by cost-effectiveness. PLoS ONE 12(8):e0182951.
Huppert, A., and G. Katriel. 2013. Mathematical modelling and prediction in infectious disease epidemiology. Clinical Microbiology and Infection 19(11):999–1005.
IOM (Institute of Medicine). 2004. Learning from SARS: Preparing for the next disease outbreak: Workshop summary. Washington, DC: The National Academies Press.
IOM. 2010a. Antibiotic resistance: Implications for global health and novel intervention strategies: Workshop summary. Washington, DC: The National Academies Press.
IOM. 2010b. The domestic and international impacts of the 2009-H1N1 influenza A pandemic: Global challenges, global solutions: Workshop summary. Washington, DC: The National Academies Press.
IOM. 2015. Assessing the use of agent-based models for tobacco regulation. Washington, DC: The National Academies Press.
Jamison, D. T., L. H. Summers, G. Alleyne, K. J. Arrow, S. Berkley, A. Binagwaho, F. Bustreo, D. Evans, R. G. A. Feachem, J. Frenk, G. Ghosh, S. J. Goldie, Y. Guo, S. Gupta, R. Horton, M. E. Kruk, A. Mahmoud, L. K. Mohohlo, M. Ncube, A. Pablos-Mendez, K. S. Reddy, H. Saxenian, A. Soucat, K. H. Ulltveit-Moe, and G. Yamey. 2013. Global health 2035: A world converging within a generation. The Lancet 382:1898–1955.
Jones, K. E., N. G. Patel, M. A. Levy, A. Storeygard, D. Balk, J. L. Gittleman, and P. Daszak. 2008. Global trends in emerging infectious diseases. Nature 451:990–993.
Kesselheim, A. S. 2010. Using market-exclusivity incentives to promote pharmaceutical innovation. New England Journal of Medicine 363:1855–1862.
Kfoury, J. 2014. The paradox of antibiotics pricing. L.E.K. Executive Insights 16(46). L.E.K. Consulting, LLC.
Knight, G. M., N. J. Dharan, G. J. Fox, N. Stennis, A. Zwerling, R. Khurana, and D. W. Dowdy. Bridging the gap between evidence and policy for infectious diseases: How can models aid public health decision-making. International Journal of Infectious Diseases 42:17–23.
KPMG. 2014. The global economic impact of anti-microbial resistance. London: KPMG, LLP.
Larson, B. A., M. P. Fox, M. Bii, S. Rosen, J. Rohr, D. Shaffer, F. Sawe, M. Wasunna, and J. L. Simon. 2013. Antiretroviral therapy, labor productivity, and sex: A longitudinal cohort study of tea pluckers in Kenya. AIDS (London, England) 27:115–123.
Laurence, Y. V., U. K. Griffiths, and A. Vassall. 2015. Costs to health services and the patient of treating tuberculosis: A Systematic literature review. Pharmacoeconomics 33(9):939–955.
Laxminarayan, R., T. V. Boeckel, and A. Teillant. 2015. The economic costs of withdrawing antimicrobial growth promoters from the livestock sector. OECD Food, Agriculture and Fisheries Papers, No. 78, Paris, France: OECD Publishing.
Lee, J. W., and W. J. McKibbin. 2004. Estimating the global economic cost of SARS. In Learning from SARS: Preparing for the next disease outbreak: Workshop summary. Washington, DC: The National Academies Press.
Maher, D., C. Dye, K. Floyd, A. Pantoja, K. Lonnroth, A. Reid, E. Nathanson, T. Pennas, U. Fruth, J. Cunningham, H. Ignatius, M. C. Raviglione, I. Koek, and M. Espinal. 2007. Planning to improve global health: The next decade of tuberculosis control. Bulletin of the World Health Organization 85(5):325–420.
McDonald, S., K. Thierfelder, and T. Walmsley. 2013. GLOBE2_DYN: Technical document and user guide. Processed.
McKibbin, W., and A. Sidorenko. 2007. The global costs of an influenza pandemic. The Milken Institute Review 18–27.
Meltzer, M. I., N. J. Cox, and K. Fukuda. 1999. The economic impact of pandemic influenza in the United States: Priorities for intervention. Emerging Infectious Diseases 5:659–671.
Menzies, N. A., G. B. Gomez, F. Bozzani, S. Chatterjee, N. Foster, I. G. Baena, Y. V. Laurence, S. Qiang, A. Siroka, S. Sweeney, S. Verguet, N. Arinaminpathy, A. S. Azman, E. Bendavid, S. T. Chang, T. Cohen, J. T. Denholm, D. W. Dowdy, P. A. Eckhoff, J. D. Goldhaber-Fiebert, A. Handel, G. H. Huynh, M. Lalli, H.-H. Lin, S. Mandal, E. S. McBryde, S. Pandey, J. A. Salomon, S.-c. Suen, T. Sumner, J. M. Trauer, B. G. Wagner, C. C. Whalen, C.-Y. Wu, D. Boccia, V. K. Chadha, S. Charalambous, D. P. Chin, G. Churchyard, C. Daniels, P. Dewan, L. Ditiu, J. W. Eaton, A. D. Grant, P. Hippner, M. Hosseini, D. Mametja, C. Pretorius, Y. Pillay, K. Rade, S. Sahu, L. Wang, R. M. G. J. Houben, M. E. Kimerling, R. G. White, and A. Vassall. 2016. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: A combined analysis of nine models. Lancet Global Health 4:e816–e826.
Musgrove, P. 1988. Is polio eradication in the Americas economically justified? Bulletin of the Pan American Health Organization 22:1–16.
NASEM (National Academies of Sciences, Engineering, and Medicine). 2016. The Ebola epidemic in West Africa. Washington, DC: The National Academies Press.
NASEM. 2017. Combating antimicrobial resistance: A One Health approach to a global threat. Washington, DC: The National Academies Press.
Neumann, G., H. Chen, G. Gao, Y. Shu, and Y. Kawaoka. 2010. H5N1 influenza viruses: Outbreaks and biological properties. Cell Research 20:51–61.
Noyce, R. S., S. Lederman, and D. H. Evans. 2018. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS ONE 13:e0188453.
NPHIL (National Public Health Institute of Liberia). 2017. Republic of Liberia 2017 annual integrated disease surveillance and response (IDSR) bulletin. Monrovia, Liberia: National Public Health Institute of Liberia.
OECD (Organisation for Economic Co-operation and Development). 2017. Low-value health care with high stakes: Promoting the rational use of antimicrobials. In Tackling wasteful spending on health. Pp. 115–158. Paris, France: OECD.
OIE (World Organisation for Animal Health). 2018a. Peste des petits ruminants, Burundi: Information received on 11/01/2018 from Dr, Déogratias Nsanganiyumwami, Directeur, Santé Animale, Ministère de l’Agriculture et de l’Elevage, Gitega, Burundi. Paris, France: OIE.
OIE. 2018b. Strengthening veterinary services through the OIE PVS pathway: Investment case and financing recommendations. Paris, France: OIE.
Ozawa, S., T. T. Yemeke, and K. M. Thompson. 2018. Systematic review of the incremental costs of interventions that increase immunization coverage. Vaccine 36:3641–3649.
Patel, J. C., J. George, J. Vuong, C. C. Potts, C. Bozio, T. A. Clark, J. Thomas, J. Schier, A. Chang, J. L. Waller, M. H. Diaz, M. Whaley, L. T. Jenkins, S. Fuller, D. E. Williams, J. T. Redd, R. R. Arthur, F. Taweh, Y. V. Walker, P. Hardy, M. Freeman, V. Katawera, G. Gwesa, M. Z. Gbanya, P. Clement, H. Khar, M. Stone, M. Fallah, T. Nyenswah, J. M. Winchell, X. Wang, L. A. McNamara, E. K. Dukubo, and L. M. Fox. Rapid laboratory identification of Neisseria meningitidis Serogroup C as the cause of an outbreak—Liberia, 2017. Morbidity and Mortality Weekly Report 66(42):1144–1147.
Pettifor, A., C. MacPhail, J. P. Hughes, A. Selin, J. Wang, F. X. Gomez-Olive, S. H. Eshleman, R. G. Wagner, W. Mabuza, N. Khoza, C. Suchindran, I. Mokoena, R. Twine, P. Andrew, E. Townley, O. Laeyendecker, Y. Agyei, S. Tollman, and K. Kahn. 2016. The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): A phase 3, randomised controlled trial. Lancet Global Health 4(12):e978–e988.
Pike, J., T. Bogich, S. Elwood, D. C. Finnoff, and P. Daszak. 2014. Economic optimization of a global strategy to address the pandemic threat. Proceedings of the National Academy of Sciences of the United States of America 111:18519–18523.
Plsek, P. E., and T. Greenhalgh. 2001. The challenge of complexity in health care. British Medical Journal 323(7313):625–628.
Potter, C. W. 2001. A history of influenza. Journal of Applied Microbiology 91:572–579.
Review on Antimicrobial Resistance. 2014. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. London: Wellcome Trust and U.K. Department of Health.
Review on Antimicrobial Resistance. 2016. Tackling drug-resistant infections globally: Final report and recommendations. London: Wellcome Trust and U.K. Department of Health.
Ross, R. 1915. Some a priori pathometric equations. British Medical Journal 1:546–547.
Sands, P., A. El Turabi, P. A. Saynisch, and V. J. Dzau. 2016. Assessment of economic vulnerability to infectious disease crises. The Lancet 388(10058):2443–2448.
Schäferhoff, M., S. Fewer, J. Kraus, E. Richter, L. H. Summers, J. Sundewall, G. Yamey, and D. T. Jamison. 2015. How much donor financing for health is channelled to global versus country-specific aid functions? The Lancet 386:2436–2441.
Schoch-Spana, M., A. Cicero, A. Adalja, G. Gronvall, T. Kirk Sell, D. Meyer, J. B. Nuzzo, S. Ravi, M. P. Shearer, E. Toner, C. Watson, M. Watson, and T. Inglesby. 2017. Global catastrophic biological risks: Toward a working definition. Health Security 15:323–328.
Shrestha, S. S., D. L. Swerdlow, R. H. Borse, V. S. Prabhu, L. Finelli, C. Y. Atkins, K. Owusu-Edusei, B. Bell, P. S. Mead, M. Biggerstaff, L. Brammer, H. Davidson, D. Jernigan, M. A. Jhung, L. A. Kamimoto, T. L. Merlin, M. Nowell, S. C. Redd, C. Reed, A. Schuchat, and M. I. Meltzer. 2011. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010). Clinical Infectious Diseases 52:S75–S82.
Siu, A., and Y. C. R. Wong. 2004. Economic impact of SARS: The case of Hong Kong. Asian Economic Papers 3:62–83.
Taubenberger, J. K. 2006. The origin and virulence of the 1918 “Spanish” influenza virus. Proceedings of the American Philosophical Society 150:86–112.
Taylor, J., M. Hafner, E. Yerushalma, R. Smith, J. Bellasio, R. Vardavas, T. Bienkowska-Gibbs, and J. Rubin. 2014. Estimating the economic costs of antimicrobial resistance: Models and results. London: Wellcome Trust.
Tebbens, R. J. D., M. A. Pallansch, S. L. Cochi, S. G. F. Wassilak, J. Linkins, R. W. Sutter, R. B. Aylward, and K. M. Thompson. 2010. Economic analysis of the Global Polio Eradication Initiative. Vaccine 29:334–343.
Tebbens, R. J. D., M. A. Pallansch, S. L. Cochi, S. G. F. Wassilak, and K. M. Thompson. 2015. An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infectious Diseases 15:389.
Thomas, R., R. Burger, A. Harper, S. Kanema, L. Mwenge, N. Vanqa, N. Bell-Mandla, P. C. Smith, S. Floyd, P. Bock, H. Ayles, N. Beyers, D. Donnell, S. Fidler, R. Hayes, K. Hauck, J. Hargreaves, D. Watson-Jones, P. Godfrey-Faussett, A. Cori, M. Pickles, N. Mandla, B. Yang, A. James, R. Vermaak, N. Makola, G. Hoddinott, V. Naidoo, V. Bond, M. Simwinga, A. Mwinga, B. Kosloff, M. Limbada, J. Bwalya, C. Ngulube, C. Fraser, S. Eshleman, Y. Agyei, V. Cummings, D. Catalano, L. Emel, L. Bunts, H. Noble, D. Burns, A. Kouda, N. Sista, A. Moore, R. White, T. Headen, E. Miller, K. Hinson, S. Vermund, M. Barnes, L. Horn, A. Mwango, M. Baldwin, S. Wolf, and E. Hughes. 2017. Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: A cross-sectional baseline survey of the HPTN 071 (PopART) trial. Lancet Global Health 5:e1133–e1141.
Thomas, R., R. Friebel, K. Barker, L. Mwenge, S. Kanema, N. Vanqa, A. Harper, N. Bell-Mandla, P. Smith, S. Floyd, P. Bock, H. Ayles, N. Beyers, S. Fidler, R. Hayes, and K. Hauck. In review. Work and home productivity of HIV-positive and HIV-negative individuals in Zambia and South Africa: A cross-sectional baseline survey of the HPTN071/PopART trial.
Thompson, K. M., and R. J. D. Tebbens. 2006. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Analysis 26:1423–1440.
Thompson, K. M., and R. J. D. Tebbens. 2007. Eradication versus control for poliomyelitis: An economic analysis. The Lancet 369:1363–1371.
Towers, S., S. Afzal, G. Bernal, N. Bliss, S. Brown, B. Espinoza, J. Jackson, J. Judson-Garcia, M. Khan, M. Lin, R. Mamada, V. M. Moreno, F. Nazari, K. Okuneye, M. L. Ross, C. Rodriguez, J. Medlock, D. Ebert, and C. Castillo-Chavez. 2015. Mass media and the contagion of fear: The case of Ebola in America. PLoS ONE 10:e0129179.
Towers, S., A. Mubayi, and C. Castillo-Chavez. 2018. Detecting the contagion effect in mass killings; a constructive example of the statistical advantages of unbinned likelihood methods. PLoS ONE 13:e0196863.
UN (United Nations). 2016. Political declaration of the high-level meeting of the general assembly on antimicrobial resistance. New York: United Nations.
UNDG (United Nations Development Group) Western and Central Africa. 2015. Socioeconomic impact of Ebola virus disease in West African countries, Addis Ababa, Ethiopia. New York: United Nations.
UNDP (United Nations Development Programme). 2016. The sustainable development goals report. New York: United Nations.
UNDP-IFRC (International Federation of Red Cross and Red Crescent Societies). 2017. A socio-economic impact assessment of the Zika virus in Latin America and the Caribbean: with a focus on Brazil, Colombia, and Suriname. New York: United Nations.
Vassall, A., S. van Kampen, H. Sohn, J. S. Michael, K. R. John, S. den Boon, J. L. Davis, A. Whitelaw, M. P. Nicol, M. T. Gler, A. Khaliqov, C. Zamudio, M. D. Perkins, C. C. Boehme, and F. Cobelens. 2011. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: A cost-effectiveness analysis. PLoS Medicine 8:e1001120.
Vassall A., L. Mangham-Jefferies, G. B. Gomez, C. Pitt, and N. Foster. 2016. Incorporating demand and supply constraints into economic evaluations in low-income and middle-income countries. Health Economics. 25(Suppl 1):95–115.
Vassall, A., M. Siapka, N. Foster, L. Cunnama, L. Ramma, K. Fielding, K. McCarthy, G. Churchyard, A. Grant, and E. Sinanovic. 2017. Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: A real-world cost analysis and economic evaluation. Lancet Global Health 5:e710–e719.
Verguet, S., C. Riumallo-Herl, G. B. Gomez, N. A. Menzies, R. M. G. J. Houben, T. Sumner, M. Lalli, R. G. White, J. A. Salomon, T. Cohen, N. Foster, S. Chatterjee, S. Sweeney, I. G. Baena, K. Lönnroth, D. E. Weil, and A. Vassall. 2017. Catastrophic costs potentially averted by tuberculosis control in India and South Africa: A modelling study. Lancet Global Health 5:e1123–e1132.
WHO (World Health Organization). 1978. Declaration of Alma-Ata. Alma-Ata, USSR: WHO.
WHO. 2013. Priority medicines for Europe and the world. Geneva, Switzerland: WHO.
WHO. 2015. Health in 2015: From MDGs to SDGs. Geneva, Switzerland: WHO.
WHO. 2017. Global TB report 2017. Geneva, Switzerland: WHO.
Wingfield, T., M. A. Tovar, D. Huff, D. Boccia, R. Montoya, E. Ramos, S. Datta, M. J. Saunders, J. J. Lewis, R. H Gilman, and C. A. Evans. 2017. A randomized controlled study of socioeconomic support to enhance tuberculosis prevention and treatment, Peru. Bulletin World Health Organization 95(4):270–280. Geneva, Switzerland: WHO.
World Bank. 2015a. Project appraisal document—regional Sahel pastoralism support project. Washington, DC: World Bank.
World Bank. 2015b. Summary on the Ebola recovery plan: Liberia—economic stabilization and recovery plan (ESRP). Washington, DC: World Bank.
World Bank. 2016. 2014–2015 West Africa Ebola crisis: Impact update. Washington, DC: World Bank.
World Bank. 2017. From panic and neglect to investing in health security: Financing pandemic preparedness at a national level. Washington, DC: World Bank.
Xiang, N., X. Li, R. Ren, D. Wang., S. Zhou, C. M. Greene, Y. Song, L. Zhou, L. Yang, C. T. Davis, Y. Zhang, Y. Wang, J. Zhao, X. Li, A. D. Iuliano, F. Havers, S. J. Olsen, T. M. Uyeki, E. Azziz-Baumgartner, S. Trock, B. Liu, H. Sui, X. Huang, Y. Zhang, D. Ni, Z. Feng, Y, Shu, and Q. Li. 2016. Assessing change in avian influenza A(H7N9) virus infections during the fourth epidemic—China, September 2015–August 2016. Morbidity Mortality Weekly Report 65:1390–1394.
Zhang, Q.-Q., G.-G. Ying, C.-G. Pan, Y.-S. Liu, and J.-L. Zhao. 2015. Comprehensive evaluation of antibiotics emission and fate in the river basins of China: Source analysis, multimedia modeling, and linkage to bacterial resistance. Environmental Science & Technology 49:6772–6782.
